重组人血管内皮抑制素联合顺铂治疗恶性胸腹水疗效观察

摘要

目的：探讨重组人血管内皮抑制素联合顺铂治疗恶性胸腹水的疗效。方法选取2013年10月至2015年10月期间在河北省唐山市人民医院就诊的恶性胸腹水86例患者，采用随机数表法分为观察组与对照组，每组43例。观察组患者采用重组人血管内皮抑制素联合顺铂治疗，对照组患者则采用顺铂治疗，两周为一个疗程。治疗一个疗程后，比较两组的治疗效果、血常规各项指标以及生活质量的差异。结果观察组患者的治疗有效率为76.7%，明显高于对照组30.2%，差异具有统计学意义（P<0.05）；治疗后，观察组患者的淋巴细胞[(1.44±0.42)×10-9/L vs (1.20±0.60)×10-9/L]、白细胞[(4.55±2.08)×10-9/L vs (3.81±1.19)×10-9/L]、血小板[(187.64±63.71)×10-9/L vs (150.42±89.82)×10-9/L]、血红蛋白[(108.55±17.66) g/L vs (99.77±17.65) g/L]水平均高于对照组，差异均具有统计学意义(P<0.05)；在生活质量方面，观察组患者各维度评分均高于对照组，差异均具有统计学意义(P<0.05)。结论采用重组人血管内皮抑制素联合顺铂治疗恶性胸腹水，不仅可有效提高治疗效果，且对患者血细胞水平影响较低，同时可以提高患者生活质量，值得临床推广使用。%Objective To observe the effects of recombinant human endostatin combined with cis-Diammine-platinum on malignant pleural effusion and ascites. Methods A total of 86 cases of patients with malignant pleural effu-sion and ascites, who admitted to Tangshan People's Hospital from October 2013 to October 2015, were selected and ran-domly divided into the treatment group (received endostatin combined with cis-Diammineplatinum therapy) and the con-trol group (received cis-Diammineplatinum therapy), with 43 cases in each group. Two weeks were taken as a course. The therapy effects, blood routine examination and life quality of the two groups were compared after a course of treat-ment. Results The therapy effects of the treatment group (76.7%) were significantly better than those of control group (30.2%), P<0.05. The lymphocytes, white blood cells, platelet, hemoglobin of the treatment group were significantly higher than those of the control group, with (1.44±0.42)×10-9/L vs (1.20±0.60)×10-9/L, (4.55±2.08)×10-9/L vs (3.81±1.19)× 10-9/L, (187.64±63.71)×10-9/L vs (150.42±89.82)×10-9/L, (108.55±17.66) g/L vs (99.77±17.65) g/L, respectively, P<0.05. The life quality in treatment group were significantly better than that in the control group (P<0.05). Conclusion End-ostatin combined with cis-Diammineplatinum can not only has a good therapy effect on the patients with malignant pleu-ral effusion and ascites, but also can improve the quality of life of patients, with lower effect on patients’blood routine examination simultaneously. It is worthy of clinical promotion.